Scarica l'app Stockscreener
1.21
5.47%
-0.07
Dopo l'orario di chiusura:
1.23
0.02
+1.65%
Precedente Chiudi:
$1.28
Aprire:
$1.3
Volume 24 ore:
637.67K
Relative Volume:
0.24
Capitalizzazione di mercato:
$3.16M
Reddito:
$212.10K
Utile/perdita netta:
$-40.19M
Rapporto P/E:
-0.000228
EPS:
-5313.2836
Flusso di cassa netto:
$-13.92M
1 W Prestazione:
-9.02%
1M Prestazione:
-18.24%
6M Prestazione:
-97.45%
1 anno Prestazione:
-99.99%
Intervallo 1D:
$1.11
$1.31
Intervallo di 1 settimana:
$1.11
$2.1899
Portata 52W:
$1.11
$27,200.00
Aditxt Inc Stock (ADTX) Company Profile
Nome
Aditxt Inc
Settore
Industria
Telefono
909-488-0844
Indirizzo
737 N. FIFTH STREET, SUITE 200, RICHMOND
Confronta ADTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
1.21 | 3.16M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aditxt Inc Borsa (ADTX) Ultime notizie
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting - Benzinga
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board - citybiz
Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier - citybuzz -
Aditxt names Evofem CEO to its board, eyes women’s health market By Investing.com - Investing.com South Africa
Aditxt names Evofem CEO to its board, eyes women’s health market - Investing.com India
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board Of Directors - MarketScreener
Aditxt (ADTX) Welcomes Saundra Pelletier to Its Board | ADTX Stock News - GuruFocus
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors | ADTX Stock News - GuruFocus
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, - GuruFocus
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6 - MarketScreener
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Bluefield Daily Telegraph
Healthcare Innovation Leaders From Evofem, Adimune, and Pearsanta Preview New Developments at Aditxt Update - Stock Titan
Aditxt (NASDAQ:ADTX) Shares Down 8.1% – Time to Sell? - Defense World
Aditxt Highlights Strategic Partnership with Evofem Biosciences - TipRanks
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline By Investing.com - Investing.com South Africa
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline - Investing.com Nigeria
Stocks In Play: Appili Therapeutics Inc. By Baystreet.ca - Investing.com Canada
Appili Therapeutics Inc. - Baystreet.ca
Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions - TipRanks
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - The Manila Times
Options Volatility and Implied Earnings Moves Today, May 29, 2025 - The Globe and Mail
Aditxt secures $233K loan from CEO Albanna - Investing.com Australia
Aditxt secures $233K loan from CEO Albanna By Investing.com - Investing.com South Africa
Aditxt Issues Unsecured Promissory Note in Strategic Move - TipRanks
Aditxt (ADTX) Cancels Acquisition Agreement with Appili Therapeu - GuruFocus
Aditxt Discusses Strategic Focus and Growth Plans - TipRanks
Aditxt to Scrap Merger Deal With Appili Therapeutics - marketscreener.com
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics | ADTX Stock News - GuruFocus
Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics - marketscreener.com
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Eagle-Tribune
Aditxt, Inc. SEC 10-Q Report - TradingView
Aditxt (NASDAQ:ADTX) Shares Down 5.5% – What’s Next? - Defense World
Aditxt Highlights Progress of ADI-100TM in Autoimmune Treatment - TipRanks
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus
Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria
Aditxt secures $256K through senior note sales - Investing.com
Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks
Aditxt Inc Azioni (ADTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aditxt Inc Azioni (ADTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):